Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriflunomide - Sanofi

Next Previous
X
Search
Drug Profile

Teriflunomide - Sanofi

Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020

Latest Information Update: 08 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antivirals; Fluorinated hydrocarbons; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Human polyomavirus infections; Neurological disorders

Most Recent Events

  • 29 Jul 2024 Genzyme completes the phase III TERIKIDS trial for Multiple sclerosis (In adolescents, In children) in USA, Belgium, Bulgaria, Canada, China, Estonia, France, Greece, Israel, Lebanon, Lithuania, Morocco, Netherlands, Macedonia, Portugal, Russia, Serbia, Spain, Slovenia, Tunisia, Turkey, Ukraine, United Kingdom, Poland, Ireland (PO) (NCT02201108) (EudraCT2011-005249-12)
  • 28 May 2024 No recent reports of development identified for preclinical development in Human-polyomavirus-infections in USA (PO, Tablet)
  • 28 Jun 2023 No recent reports of development identified for research development in Neurological-disorders in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top